Antibacterial ability is vital in biological approaches as well as functional biomaterials. Besides, cytocompatibility aspect of biologic media, tissue and organs is always concern for appropriate synthesis. From the past, metallic/oxide phases of silver (Ag) material in various macro, micro or nano configurations have been widely used for antibacterial targets. While, background of Ag toxicity within particle, film and composites is posing gradual ion release affected by molecular bounding. Recent researches conducted to control, optimize and neutralize Ag limitations finding the benefits of ideal (∼ 100%) mediation against both Gram-negative and Gram-positive bacteria. Whereas, non-degradable releases history is still a challenge and its longer accumulation may cause to disrupt biostructures and disease risk. Thus, facile development of large-area organic materials with switchable bacteria toxicity and normal cell compatibility function is interesting for concerned approaches. Here, smart positively-charged stable arginine amino acid incorporated mono layer graphene (Arg-EMGr) nanobiocomposite introduced as useful antibacterial and safe bactericidal agent competitive with Ag direct. The immunity characteristic versus Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) comparably assessed with graphene oxide (GO) and different concentrations GO-AgNPs morphology. As cell viability matter, 1,3,5,7-days vitro culture assay shown attachment proliferation and cytotoxicity due to short interaction.
The genus Burkholderia consists of diverse species which includes both "friends" and "foes." Some of the "friendly" Burkholderia spp. are extensively used in the biotechnological and agricultural industry for bioremediation and biocontrol. However, several members of the genus including B. pseudomallei, B. mallei, and B. cepacia, are known to cause fatal disease in both humans and animals. B. pseudomallei and B. mallei are the causative agents of melioidosis and glanders, respectively, while B. cepacia infection is lethal to cystic fibrosis (CF) patients. Due to the high rate of infectivity and intrinsic resistance to many commonly used antibiotics, together with high mortality rate, B. mallei and B. pseudomallei are considered to be potential biological warfare agents. Treatments of the infections caused by these bacteria are often unsuccessful with frequent relapse of the infection. Thus, we are at a crucial stage of the need for Burkholderia vaccines. Although the search for a prophylactic therapy candidate continues, to date development of vaccines has not advanced beyond research to human clinical trials. In this article, we review the current research on development of safe vaccines with high efficacy against B. pseudomallei, B. mallei, and B. cepacia. It can be concluded that further research will enable elucidation of the potential benefits and risks of Burkholderia vaccines.